Table 2. Treatment Tolerability.
This table lists characteristics associated with tolerability of docetaxel and AT-101 including duration of therapy and reason for discontinuation
| Overall | Arm A (Docetaxel) | Arm B (Pulse Dose AT-101) | Arm C (Metronomic AT-101) | ||
|---|---|---|---|---|---|
| n | 35 | 13 | 11 | 11 | |
| Duration of Treatment | |||||
| # cycles completed | Mean | 4.0 | 4.0 | 3.6 | 4.3 |
| Median (range) | 4 (1–8) | 4 (1–7) | 3 (1–8) | 4 (1–8) | |
| Dose Modifications, n (%) | |||||
| 0 | 23 (66%) | 8 (61%) | 8 (72%) | 7 (64%) | |
| 1 | 10 (28%) | 3 (23%) | 3 (27%) | 4 (36%) | |
| 2 | 2 (6%) | 2 (15%) | 0 (0%) | 0 (0%) | |
| Reason for treatment discontinuation, n (%) | |||||
| Intercurrent Illness | 7 (20%) | 3 (23%) | 2 (18%) | 2 (18%) | |
| Unacceptable Toxicity | 2 (6%) | 1 (8%) | 1 (9%) | 0 (0%) | |
| Progression disease | 17 (48%) | 5 (38%) | 6 (55%) | 6 (55%) | |
| Patient non-compliance | 7 (20%) | 2 (15%) | 2 (18%) | 3 (27%) | |
| Other | 2 (6%) | 2 (16%) | 0 (0%) | 0 (0%) | |